Inhaled Nitric Oxide Market Size, Share, Trends, Growth Outlook

Inhaled Nitric Oxide Market is estimated to increase at a Compounded Annual Growth Rate of 7.7% CAGR over the forecast period from 2024 to 2030

The Inhaled Nitric Oxide Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Gas, Delivery Systems), By Application (Neonatal Respiratory Treatment, Asthma and COPD, Acute Respiratory Distress Syndrome, Malaria Treatment, Tuberculosis Treatment, Others).

An Introduction to Inhaled Nitric Oxide Market in 2024

In 2024, the market for inhaled nitric oxide (NO) remains pivotal in the management of various cardiopulmonary disorders, offering targeted vasodilation and improving oxygenation in critically ill patients. Inhaled nitric oxide, a selective pulmonary vasodilator, acts by relaxing vascular smooth muscle in the pulmonary circulation, leading to improved ventilation-perfusion matching and reduced pulmonary hypertension. It is used primarily in neonatal respiratory distress syndrome (RDS), persistent pulmonary hypertension of the newborn (PPHN), and acute respiratory distress syndrome (ARDS) in adults. Advancements in delivery systems, such as precision dosing devices and integrated monitoring technologies, have enhanced the safety and efficacy of inhaled NO therapy, allowing for tailored treatment regimens and improved outcomes in patients with cardiopulmonary compromise.

Market Trend: Expansion of Applications Beyond Neonatal Respiratory Distress Syndrome

Inhaled nitric oxide (iNO) is experiencing a prominent trend toward the expansion of applications beyond neonatal respiratory distress syndrome (NRDS). While iNO has been traditionally used for the treatment of NRDS in newborns, there is growing interest in its potential therapeutic benefits across a broader range of respiratory and cardiovascular conditions. Clinical research and trials are exploring the use of iNO in conditions such as acute respiratory distress syndrome (ARDS), pulmonary hypertension, and chronic obstructive pulmonary disease (COPD), as well as in perioperative settings for improving oxygenation and reducing pulmonary complications. This trend toward diversification of iNO applications presents opportunities for market expansion and innovation in the development of iNO delivery systems and treatment protocols.

Market Driver: Rising Prevalence of Respiratory and Cardiovascular Diseases

A key driver for the inhaled nitric oxide market is the rising prevalence of respiratory and cardiovascular diseases. Conditions such as ARDS, pulmonary hypertension, and COPD affect millions of individuals worldwide, leading to significant morbidity and mortality. Inhaled nitric oxide, with its selective pulmonary vasodilatory effects, offers a targeted therapeutic approach for managing pulmonary hypertension and improving oxygenation in patients with acute and chronic respiratory disorders. Additionally, advancements in critical care medicine, surgical techniques, and perioperative management have increased the demand for iNO as an adjunctive therapy to optimize patient outcomes in various clinical settings. The growing burden of respiratory and cardiovascular diseases drives the need for effective and innovative treatment options, driving the market growth for inhaled nitric oxide.

Market Opportunity: Expansion into Developing Countries and Homecare Settings

An emerging opportunity in the inhaled nitric oxide market lies in the expansion into developing countries and homecare settings. While iNO therapy has been primarily utilized in advanced healthcare facilities and intensive care units (ICUs) in developed regions, there is a significant unmet need for pulmonary vasodilator therapies in resource-limited settings. Developing countries often face challenges in accessing and affording advanced medical treatments for respiratory and cardiovascular conditions. By expanding the availability of iNO therapy and developing cost-effective delivery systems, manufacturers can address the needs of underserved populations and improve access to life-saving treatments. Additionally, there is potential for iNO therapy to be administered in homecare settings for select patient populations, offering greater convenience, comfort, and continuity of care. By exploring these opportunities, companies can broaden their market reach, enhance patient care, and contribute to improving global health outcomes in respiratory and cardiovascular diseases.

Inhaled Nitric Oxide Market Share Analysis: Neonatal Respiratory Treatment

In the Inhaled Nitric Oxide Market, the segment experiencing the fastest growth is Neonatal Respiratory Treatment. Inhaled nitric oxide (iNO) is a vasodilator and selective pulmonary vasodilator that is commonly used in neonates with respiratory distress syndrome (RDS) and persistent pulmonary hypertension of the newborn (PPHN). iNO works by dilating the pulmonary vasculature, improving oxygenation, and reducing pulmonary vascular resistance, thereby improving oxygen delivery to the tissues. With increasing awareness about the benefits of iNO therapy in managing respiratory conditions in neonates, including preterm infants with RDS and term infants with PPHN, there is a growing demand for iNO in neonatal intensive care units (NICUs) and specialized newborn care facilities. Hospitals and healthcare facilities catering to neonatal care are key end-users of iNO therapy, where it is administered using specialized delivery systems tailored to the needs of premature and critically ill infants. Additionally, ongoing research and clinical trials exploring the potential applications of iNO in other neonatal respiratory conditions further contribute to its expanding market share in the neonatal respiratory treatment segment. Consequently, the neonatal respiratory treatment segment is poised for significant growth in the inhaled nitric oxide market.

Inhaled Nitric Oxide Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAir Liquide Healthcare, Bellerophan Therapeutics Inc, BOC Healthcare, HALMA PLC, LINDE PLC, Mallinckrodt Pharmaceuticals, Matheson Tri-Gas Inc, Merck KGaA, Nu-Med Plus Inc, Perma Pure LLC, Praxair Distribution Inc

Inhaled Nitric Oxide Market Segmentation

By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Inhaled Nitric Oxide Market Companies

Air Liquide Healthcare
Bellerophan Therapeutics Inc
BOC Healthcare
HALMA PLC
LINDE PLC
Mallinckrodt Pharmaceuticals
Matheson Tri-Gas Inc
Merck KGaA
Nu-Med Plus Inc
Perma Pure LLC
Praxair Distribution Inc

Reasons to Buy the Inhaled Nitric Oxide Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Inhaled Nitric Oxide Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Inhaled Nitric Oxide Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Inhaled Nitric Oxide Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Inhaled Nitric Oxide Market Size Outlook, $ Million, 2021 to 2030
3.2 Inhaled Nitric Oxide Market Outlook by Type, $ Million, 2021 to 2030
3.3 Inhaled Nitric Oxide Market Outlook by Product, $ Million, 2021 to 2030
3.4 Inhaled Nitric Oxide Market Outlook by Application, $ Million, 2021 to 2030
3.5 Inhaled Nitric Oxide Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Inhaled Nitric Oxide Industry
4.2 Key Market Trends in Inhaled Nitric Oxide Industry
4.3 Potential Opportunities in Inhaled Nitric Oxide Industry
4.4 Key Challenges in Inhaled Nitric Oxide Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Inhaled Nitric Oxide Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Inhaled Nitric Oxide Market Outlook by Segments
7.1 Inhaled Nitric Oxide Market Outlook by Segments, $ Million, 2021- 2030
By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others

8 North America Inhaled Nitric Oxide Market Analysis and Outlook To 2030
8.1 Introduction to North America Inhaled Nitric Oxide Markets in 2024
8.2 North America Inhaled Nitric Oxide Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Inhaled Nitric Oxide Market size Outlook by Segments, 2021-2030
By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others

9 Europe Inhaled Nitric Oxide Market Analysis and Outlook To 2030
9.1 Introduction to Europe Inhaled Nitric Oxide Markets in 2024
9.2 Europe Inhaled Nitric Oxide Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Inhaled Nitric Oxide Market Size Outlook by Segments, 2021-2030
By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others

10 Asia Pacific Inhaled Nitric Oxide Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Inhaled Nitric Oxide Markets in 2024
10.2 Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Inhaled Nitric Oxide Market size Outlook by Segments, 2021-2030
By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others

11 South America Inhaled Nitric Oxide Market Analysis and Outlook To 2030
11.1 Introduction to South America Inhaled Nitric Oxide Markets in 2024
11.2 South America Inhaled Nitric Oxide Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Inhaled Nitric Oxide Market size Outlook by Segments, 2021-2030
By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others
12 Middle East and Africa Inhaled Nitric Oxide Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Inhaled Nitric Oxide Markets in 2024
12.2 Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Inhaled Nitric Oxide Market size Outlook by Segments, 2021-2030
By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Air Liquide Healthcare
Bellerophan Therapeutics Inc
BOC Healthcare
HALMA PLC
LINDE PLC
Mallinckrodt Pharmaceuticals
Matheson Tri-Gas Inc
Merck KGaA
Nu-Med Plus Inc
Perma Pure LLC
Praxair Distribution Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Gas
Delivery Systems
By Application
Neonatal Respiratory Treatment
Asthma and COPD
Acute Respiratory Distress Syndrome
Malaria Treatment
Tuberculosis Treatment
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)